Protalix BioTherapeutics Inc (PLX) VP, CFO Yossi Maimon sells 70,000 Shares

VP, CFO of Protalix BioTherapeutics Inc (PLX, Financial) Yossi Maimon sells 70,000 shares of PLX on 09/07/2010 at an average price of $8.07 a share.

Protalix Biotherapeutics Inc has a market cap of $661.6 million; its shares were traded at around $8.18 with and P/S ratio of 1741.1.

PLX is in the portfolios of Stanley Druckenmiller of Duquesne Capital Management, LLC, Steven Cohen of SAC Capital Advisors.

Directors and Officers Recent Trades:

  • Sell: Executive VP, R&D Yoseph Shaaltiel sold 53,027 shares of PLX stock on 08/06/2010 at the average price of 7. Yoseph Shaaltiel owns at least 763,754 shares after this. The price of the stock has increased by 16.86% since.

  • Sell: Executive VP, R&D Yoseph Shaaltiel sold 52,973 shares of PLX stock on 06/21/2010 at the average price of 7. Yoseph Shaaltiel owns at least 816,781 shares after this. The price of the stock has increased by 16.86% since.

  • Sell: Executive VP, R&D Yoseph Shaaltiel sold 12,691 shares of PLX stock on 04/29/2010 at the average price of 7. Yoseph Shaaltiel owns at least 869,754 shares after this. The price of the stock has increased by 16.86% since.

  • Sell: Executive VP, R&D Yoseph Shaaltiel sold 1,309 shares of PLX stock on 04/14/2010 at the average price of 7. Yoseph Shaaltiel owns at least 882,445 shares after this. The price of the stock has increased by 16.86% since.

  • Sell: Executive VP, R&D Yoseph Shaaltiel sold 380,000 shares of PLX stock on 03/25/2010 at the average price of 7.05. Yoseph Shaaltiel owns at least 883,754 shares after this. The price of the stock has increased by 16.03% since.